Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4371-4380 Newer>

BusinessWeek December 3, 2007 Eamon Javers	Salt Could Soon Be on the Fed's Hit List The FDA is looking again at the role sodium plays in heart disease - and foodmakers are scrambling.
BusinessWeek December 3, 2007 Arlene Weintraub	Is the Hip Bone Connected To a Fee? An investigation alleges some orthopedics makers have showered surgeons with fees and perks.
The Motley Fool November 21, 2007 Rich Smith	Medtronic Motors Ahead Shares of the medical equipment maker soared yesterday and continue to buck the downtrend on Wall Street, in the wake of a fiscal Q2 2008 earnings report that exceeded expectations for both sales and profits.
The Motley Fool November 21, 2007 Brian Lawler	Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note.
The Motley Fool November 21, 2007 Brian Lawler	Pfizer Finds an Old Friend Pfizer announces its purchase of partner Coley Pharmaceutical, securing Coley's novel technology for targeting toll-like receptors.
The Motley Fool November 21, 2007 Brian Orelli	Depression Hits Biovail An FDA decision on Biovail's depression drug could be another six months away.
The Motley Fool November 21, 2007 Brian Orelli	Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note.
The Motley Fool November 21, 2007 Brian Lawler	Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded.
The Motley Fool November 21, 2007 Brian Orelli	Black Friday Bargain Stock: Dr. Reddy's Laboratories Is Dr. Reddy's Laboratories a good value right now? Growth is slowing at the generic drugmaker, but is it enough to justify the drop in price?
The Motley Fool November 20, 2007 Brian Orelli	Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future.
<Older 4371-4380 Newer> Return to current articles.